Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

ABSTRACT:

Background

Major depressive disorder (MDD) is a highly heterogeneous condition in terms of symptom presentation and, likely, underlying pathophysiology. Accordingly, it is possible that only certain individuals with MDD are well-suited to antidepressants. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes of depression, such as neuroticism, anhedonia, and cognitive control deficits.

Methods

Within an 8-week multisite trial of sertraline v. placebo for depressed adults (n = 216), we examined whether the combination of machine learning with a Personalized Advantage Index (PAI) can generate individualized treatment recommendations on the basis of endophenotype profiles coupled with clinical and demographic characteristics.

R

SUBMITTER: Webb CA 

PROVIDER: S-EPMC6314923 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature